Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 43Gastrointestinal 4Genitourinary 2CNS 2Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Wilms Tumor 1Urinary Bladder Neoplasms 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Pleuropulmonary blastoma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Cholangiocarcinoma 1

Interventions

Prednisone 122Docetaxel 118enzalutamide 101pembrolizumab 96Sunitinib 86Leuprolide 84Abiraterone Acetate 83Nivolumab 78Gemcitabine 76bicalutamide 54Radiotherapy 54Goserelin 54Bevacizumab 54Cisplatin 52Magnetic Resonance Spectroscopy 49Everolimus 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 46Sorafenib 40Carboplatin 40Paclitaxel 37Radiosurgery 36atezolizumab 35abiraterone 33pazopanib 32cabozantinib 32Ipilimumab 32Axitinib 30Cyclophosphamide 29Androgen Antagonists 29Radiation 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Ado-Trastuzumab Emtansine × Genitourinary × Clear all
NCT02452554 2022-01-13

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Children's Oncology Group

Phase 2 Completed
62 enrolled 15 charts
CNSGenitourinarySarcoma

Pleuropulmonary blastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Synovial, Neurofibrosarcoma

NCT02999672 2019-08-28

KAMELEON

Hoffmann-La Roche

Phase 2 Completed
20 enrolled 14 charts
GastrointestinalGenitourinary

Urinary Bladder Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡